AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04483310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR therapy.
Description: MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
Study NCT04483310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breathing-distraction exercise
Description: The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
Study NCT01959451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: see Arm description
Study NCT01959451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: see arm description
Study NCT02713802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cudafol(R) (propofol, 1% [10 mg/mL])
Description: Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
Study NCT02713802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan(R) (propofol, 1% [10 mg/mL])
Description: Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
Study NCT05291780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
Description: The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week).
Study NCT01132326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
Study NCT00526643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
Study NCT00526643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
Study NCT00526643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 60 mg/m2 on day 1 for 4 cycles
Study NCT00077064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril
Description: Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
Study NCT01291979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
Study NCT01291979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study NCT01876316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: single oral administration of 400mg of moxifloxacin
Study NCT01876316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral administration of 400mg of placebo
Study NCT01691833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
Study NCT01691833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients that are Vitamin D deficient maybe randomized to the placebo group D.
Study NCT02845401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop NA therapy
Description: Cases will stop antiviral therapy
Study NCT01016080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutathione
Description: 250 mg capsules, twice daily, orally
Study NCT01016080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 250 mg capsules, twice daily, orally
Study NCT02162784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Procaterol, 180/10mcg X1
Description: one puff
Study NCT02162784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/procaterol 180/10 mcg X 2
Description: 2 puffs
Study NCT02162784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA MDI 100mcg X2
Description: HFA MDI, 100mcg, 2 puffs
Study NCT00768820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate, fluoxetin, risperidone
Description: first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
Study NCT00885092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
Study NCT00885092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)
Description: Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
Study NCT00885092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lens (ACUVUE® Oasys™)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study NCT00885092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens (PureVision®)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study NCT02753855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: A single dose of telavancin as a 1-hour intravenous infusion
Study NCT04759690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
Study NCT04759690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
Study NCT04759690 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise group
Description: Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
Study NCT00626925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
Study NCT01911728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study NCT01911728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral
Study NCT01911728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral
Study NCT01911728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral
Study NCT01911728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral
Study NCT01445652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear
Study NCT01445652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles per current prescription
Study NCT01410955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formula
Description: Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
Study NCT01410955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
Study NCT01635257 — intervention group
Intervention type: OTHER
Intervention: Ultrasound scan
Description: A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
Study NCT00781391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin tablets
Description: Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
Study NCT00781391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban tablets (high dose regimen-60mg)
Description: Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
Study NCT00781391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban tablets (low dose regimen-30mg)
Description: Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
Study NCT00781391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo warfarin
Description: placebo warfarin
Study NCT00781391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo edoxaban
Description: placebo edoxaban
Study NCT04032665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rivaroxaban
Description: In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
Study NCT04535947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
Study NCT04535947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (1.0%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
Study NCT01017354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidroferol® (ES)
Description: 24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
Study NCT01017354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ViDe3 (CH)
Description: 60000 vitamin D3 orally and once per month
Study NCT01017354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ViDe3 (CH)
Description: 24000 Vitamin D3 orally and once per month
Study NCT01673906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic work up
Description: Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
Study NCT01185626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCP care
Study NCT00762944 — intervention group
Intervention type: DEVICE
Intervention: Biomet TMJ Replacement System
Description: Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
Study NCT03802123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C
Description: ⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
Study NCT02495480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel disposable sheath
Description: a new sheath will be placed on the endoscope in sheathed group
Study NCT04878835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intralesional ranibizumab
Description: Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
Study NCT03132428 — intervention group
Intervention type: DRUG
Intervention: INOmax
Description: Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
Study NCT02471092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skim milk products
Description: Milk treatments will be served with 58g of breakfast cereal.
Study NCT02471092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skim milk products
Description: Milk treatments will be served with 58g of breakfast cereal.
Study NCT02471092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Skim milk products
Description: Milk treatments will be served with 58g of breakfast cereal.
Study NCT03865602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sepsis Transition And Recovery (STAR)
Description: In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
Study NCT03865602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
Study NCT01510275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined use of RESPIVOL® and RESPILIFT®
Description: Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
Study NCT01510275 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combined use of RESPIVOL® and RESPILIFT®
Description: Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
Study NCT02240433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: LY2157299 administered orally
Study NCT02240433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib administered orally
Study NCT00149305 — intervention group
Intervention type: OTHER
Intervention: Genetic analyses
Study NCT04641481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152
Description: BBV152 (6µg-Algel - Imidazoquinoline)
Study NCT04641481 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (PBS+Alum, without antigen)
Study NCT00901628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 300mg (0.75%, 40cc) intraoperative periarticular injection
Study NCT00901628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate
Description: 10mg intraoperative periarticular injection
Study NCT00901628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: 30 mg intraoperative periarticular injection
Study NCT00901628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: 300 microgram (1:1000) intraoperative periarticular injection
Study NCT05624021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moist heating
Description: A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
Study NCT00832572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
Study NCT01362439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
Study NCT02960100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard HPV vaccine information (HPV VIS)
Study NCT02960100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Receive targeted HPV vaccine narrative-style video
Study NCT02960100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02960100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04284449 — intervention group
Intervention type: OTHER
Intervention: Whole-practice cognitive optimization
Description: This intervention is a whole-practice intervention that may include nutritional assessment \& supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
Study NCT00975845 — intervention group
Intervention type: OTHER
Intervention: BioCleanse Tibialis tendon
Description: Outcomes of anterior cruciate replacement will be evaluated
Study NCT01238055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Sunitinib
Description: Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks
Study NCT01238055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel only
Description: Docetaxel 60 mg/m2 iv
Study NCT00832572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match ranolazine administered twice a day for 6 weeks
Study NCT00614081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced dynamic MRI
Study NCT02456402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon
Description: If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
Study NCT02456402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.